No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ENGN enGene Holdings
- 15.500
- +0.780+5.30%
Close Apr 26 16:00 ET
- 15.200
- -0.300-1.94%
Post 17:16 ET
675.51MMarket Cap-8757P/E (TTM)
15.500High14.000Low113.42KVolume14.920Open14.720Pre Close1.70MTurnover0.68%Turnover RatioLossP/E (Static)43.58MShares47.17052wk High10.83P/B260.56MFloat Cap6.69052wk Low--Dividend TTM16.81MShs Float47.170Historical High--Div YieldTTM10.19%Amplitude6.690Historical Low14.994Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | EnGene Holdings Inc : Wells Fargo Initiates With Overweight Rating; Price Target $30
EnGene Holdings Price Target Announced at $34.00/Share by Guggenheim
EnGene Holdings Price Target Announced at $34.00/Share by Guggenheim
Express News | enGene Holdings Inc : Rosenblatt Securities Initiates Coverage With Buy Rating and $34 Target Price
Press Release: Engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development Canada NewsWire BOSTON and MONTREAL, April 9, 2024 BOSTON and MONTREAL, April 9, 2024
EnGene Holdings Initiated at Buy by UBS
EnGene Holdings Initiated at Buy by UBS
UBS Initiates Coverage on EnGene Holdings With Buy Rating, $37 Price Target
UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target.
Comments
Borrow rate is the highest on the market
$enGene Holdings(ENGN.US$ Shorts are going to cover this week due to such a high rate. There is also less than 400 shares available. Projected is 31.00 but that is after covering. They may wait until 50.00 to short it again unless lockup has ended for them, then they will sell.
6
The appointment of Lee Giguere, an experienced public biotech legal executive, is expected to strongly support enGene's growth as the company advances the development of EG-70 in its ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer.
$enGene Holdings(ENGN.US$ dont you want to pop yet? what are you waiting for?
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg